Debiopharm has entered into a collaboration with Merck KGaA and Pfizer to evaluate Debio 1143, an oral, small molecule inhibitor of IAPs (Inhibitor of Apoptosis Proteins), in combination with avelumab, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, in advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).   Debio 1143 is currently in Phase II development for head and neck and ovarian cancer. Avelumab is under investigation across a broad range of tumor types by Merck K...